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ABSTRACT 
Objective: The principal objective of the study was to synthesize and evaluate the biological activities of a novel class of 5-benzylidene substituted 
rhodanine derivatives as antimicrobial agents. 
Methods: All the synthesized compounds (D1-D10) were screened for their antimicrobial activities using microdilution methods as per the 
reported procedure. All compounds were evaluated as potential antimicrobial agents against gram-positive bacteria: Bacillus cereus, Staphylococcus 
aureus, gram negative bacteria: Escherichia coli Pseudomonas aeruginosa and Klebsiella pneumoniae Fungal cultures used in the study were 
Aspergillus niger, Candida albicans, Candida parapsilosis, Candida tropicalis and Candida glabrata. 
Results: Compound D6 showed good antifungal activity in the MIC range 16μg/ml against Candida tropicalis and Compound D10 showed good 
antifungal activity in the MIC range 16μg/ml against Candida glabrata. Compounds D2 and D5 showed good antibacterial activity at 32μg/ml. all the 
other compounds showed moderate antibacterial activity.  
Conclusion: Based on the above results, it can be concluded that the compounds may lead to the development of more potent antimicrobial drug 
candidates in the near future. 
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INTRODUCTION 
Design, synthesis and development of pharmaceutically active 
molecules have always been a primary objective of medicinal 
chemistry. Treatment of infectious diseases is a challenging task for 
researchers and due to the increasing number of multidrug-resistant 
microbial pathogens, the discovery of new molecules to combat drug 
resistance is always a necessity [1-6]. The existing antimicrobial drugs 
for the treatment of infectious diseases are insufficient to protect us 
for the long term because of an increasing number of resistant strains. 
Hence there is an emergent need for the development of newer 
antimicrobial agents with a new mode of action. Rhodanines are 
accepted as advantaged heterocycles in medicinal chemistry as one of 
the 4-thiazolidinones subtypes [7-11]. Thioxo-thiazolidinone 
(Rhodanine) and its derivatives [12, 13] are reported to have a broad 
spectrum of biological activities such as antibacterial [14-19], 
antifungal [20-22], anti-diabetic [23, 24], anti-tubercular [25-27] 
anticancer [28, 29] anti-HIV [30-38] and antimalarial [39]. Rhodanine 
derivatives have been investigated for Alzheimer’s disease also [40, 
41]. Rhodanine (2-thioxothiazolidin-4-one) can be used for chemical 
modifications such as N-3 and/or “active methylene” C-5 substitution 
can be found that are capable of generating potential for new bioactive 
compounds [42, 43]. We, therefore, took up designing new chemical 
entity of 3-[(dialkylamino) alkyl]-2-thioxothiazolidinone (fig. 1) by 
substituting various benzylidene derivatives at 5th position and the 
evaluation of their in vitro antimicrobial activity. In this study, we 
report in vitro activity of some very potent 3-(dialkylamino) alkyl 
substituted rhodanine derivatives.  
 
 
Fig. 1: General structure of designed molecular framework 
MATERIALS AND METHODS 
Synthesis 
All the chemicals (reagent grade) were obtained from commercial 
sources and were used as supplied without further purification. 
Melting points were determined in open capillary tubes on an 
electrically heated block and are uncorrected. The reaction progress 
and purity of the synthesized compounds were monitored by 
analytical thin-layer chromatography (TLC) on pre-coated silica gel 
plates (Merck India Ltd). IR spectra (max in cm-1) of the compounds 
were recorded on Perkin Elmer’s FT-IR RX1 PC spectrophotometer. 
1H NMR and 13C NMR spectra were recorded on Bruker AVANCE III 
spectrometers (operating at 500 MHz for 1H, and 125 MHz 
respectively for 13C) in deuterated solvents with TMS as internal 
reference (chemical shifts  in ppm). Electron Spray Ionization Mass 
spectra (ESI-HRMS) were recorded on Thermo Scientific Exactive 
plus Orbitrap spectrometer. All spectral analysis data were under 
the assigned structures. All the compounds were characterised by 
TLC, IR, 1H and 13C NMR, and HRMS. All the chemicals and solvents 
were procured from Sigma-Aldrich/Merck India Ltd. 5-benzylidene 
substituted Rhodanine containing heterocycles were synthesized as 
per the reported procedure. 
Different derivatives were synthesized (table 1) by the reaction of N–
substituted Rhodanine (1), substituted benzaldehyde (2) and 
ammonium acetate in a minimum amount of acetic acid [44]. Stirred and 
refluxed the mixture at 80-85 °C. TLC was checked. After completion of 
the reaction, the reaction mixture was washed with ethyl acetate and 
dried in a rota vapour to get (3) in good to excellent yield 
5-Benzylidene-3-(2-(dimethylamino) ethyl)-2-thioxothiazolidin 
-4-one (D1) 
The title compound was synthesized from 3-(2-(dimethylamino) 
ethyl)-2-thioxothiazolidin-4-one (0.5g, 0.0024 mol), benzaldehyde 
(0.24 ml, 0.0024 mol) and ammonium acetate (0.37 g. 0.0048 mol) in 
a minimum amount of acetic acid. Stirred and refluxed the reaction 
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mixture at 80-85 °C for 1.5 h. The reaction was monitored with TLC. 
After completion of the reaction, the reaction mixture was washed 
with ethyl acetate and the residue was dried under reduced 
pressure. Then the residue was dissolved in chloroform and washed 
with water. The chloroform layer was evaporated and then again, it 
was dissolved in a minimum amount of chloroform (5 ml). It was 
kept in a freezer overnight. Brown coloured solid was obtained, 
which was separated by filtering it with the help of sintered crucible.
  
Table 1: Structures of newly designed compounds (D1-D10) 
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The title compound was synthesized as per the procedure for 
compound D1. 3-(2-(dimethylamino) ethyl)-2-thioxothiazolidin-4-
one (0.5g, 0.0024 mol), 4-ethylbenzaldehyde (0.328 ml, 0.0024 mol), 
and ammonium acetate (0.369g, 0.0048 mol) in minimum amount of 
acetic acid was taken as reaction mixture.  
3-(2-(dimethylamino)ethyl)-5-(4-methylbenzylidene)-2-
thioxothiazolidin-4-one (D3) 
The title compound was synthesized as per the procedure for 
compound D1 by taking 3-(2-(dimethylamino)ethyl)-2-thioxo-
thiazolidin-4-one (0.5g, 0.0024 mol), 4-methylbenzaldehyde (0.254 
ml, 0.00215 mol) and ammonium acetate (0.37g, 0.0048 mol) in 
minimum amount of acetic acid.  
3-(2-(diethylamino)ethyl)-5-(4-ethyl benzylidene)-2-thioxo-
thiazolidin-4-one (D4) 
The title compound was synthesized as per the procedure for 
compound D1 by taking 3-(2-diethylamino) ethyl-2-
thioxothiazolidine-4-one (0.5g, 0.0021 mol), 4-ethylbenzaldehyde 
(0.28 ml, 0.0021 mol) and ammonium acetate (0.324g, 0.0042 mol) 
in minimum amount of acetic acid.  
3-(2-(dimethylamino)ethyl)-5-(2-methylbenzylidene-2-
thioxothiazolidin-4-one (D5) 
The title compound was synthesized as per the procedure for 
compound D1 by taking 3-(2-(diethylamino)ethyl)-2-thioxo-
thiazolidin-4-one (0.5g, 0.0024 mol), 2-methylbenzaldehyde (0.277 
ml, 0.0024 mol) and ammonium acetate (0.37g, 0.0048 mol) in 
minimum amount of acetic acid. 
3-(2-(dimethylamino)ethyl)-5-(4-isopropylbenzylidene)-2-
thioxothiazolidin-4-one (D6) 
The title compound was synthesized as per the procedure for 
compound D1 by taking 3-(2-(dimethylamino)ethyl)-2-
thioxothiazolidin-4-one (0.5g, 0.0024 mol), isopropyl benzaldehyde 
(0.356g, 0.0024 ml), and ammonium acetate (0.37g, 0.0048 mol) in 
minimum amount of acetic acid.  
5-benzyliden-3-(2-diethylamino)ethyl)-2-thioxothiazolidin-4-
one (D7) 
The title compound was synthesized as per the procedure for 
compound D1 by taking 3-(2-(diethylamino)ethyl)-2-
thioxothiazolidin-4-one (0.5g, 0.0021 mol), benzaldehyde (0.21 ml, 
0.0021 mol), and ammonium acetate (0.3237g, 0.0042 mol) in 
minimum amount of acetic acid.  
3-(2-(diethylamino)ethyl)-5-(4-methylbenzylidene)-2-thioxo-
thiazolidin-4-one (D8) 
The title compound was synthesized as per the procedure for 
compound D1 by taking 3-(2-(diethylamino)ethyl)-2-thioxo-
thiazolidin-4-one (0.5g, 0.0021 mol), 4-methylbenzaldehyde 
(0.252g, 0.0021 mol), and ammonium acetate (0.32g, 0.0042 mol) in 
minimum amount of acetic acid.  
3-(2-(diethylaminoethyl)-5-(2-methylbenzylidene)-2-
thioxothiazolidin-4-one (D9) 
The title compound was synthesized as per the procedure for 
compound D1 by taking 3-(2-(diethylamino)ethyl)-2-
thioxothiazolidin-4-one (0.5g, 0.0021 mol), 2-methylbenzaldehyde 
(0.252g, 0.0021 mol) and ammonium acetate (0.32g, 0.0042 mol) in 
the minimum amount of acetic acid.  
3-(2-(diethylamino)ethyl)-5-(4-isopropylbenzylidene)-2-
thioxothiazolidin-4-one (D10) 
The title compound was synthesized as per the procedure for 
compound D1 by taking 3-(2-(diethylamino) ethyl)-2-
thioxothiazolidin-4-one (0.5g, 0.0021 mol), 4-isopropyl-
benzaldehyde (0.32 ml, 0.0021 mol) and ammonium acetate (0.32g, 
0.0042 mol) in the minimum amount of acetic acid.  
Biological assays 
Antifungal assay 
Test fungal pathogens 
Fungal cultures used in the study were Aspergillus niger, Candida 
albicans, Candida parapsilosis,, Candida tropicalis and Candida 
glabrata. All the strains used were MTCC and were procured from 
Microbial Type Culture Collection and Gene Bank, CSIR-IMTECH, 
Chandigarh, India. 
Sub-culturing of test organisms 
All reference fungal cultures were subcultured on potato dextrose 
agar. The fungal slant was incubated for 48h at 30 °C. Mcfarland 
density (0.5 on the Mcfarland scale) of fungal culture was adjusted in 
normal saline to achieve the final concentration of 1 x 105cfu/ml of 
each test organism individually. In the case of Aspergillus niger, 
conidial suspensions were harvested after isolates were subcultured 
on PDA at 30 °C to 7 d and were suspended in normal saline. 
Aspergillus niger inocula were then prepared spectrophotometrically 
and further diluted in normal saline to obtain a final inoculum 
concentration of 1 x 105cfu/ml. This had been used as adjusted 
inoculum for all the further studies. 
Determination of MIC 
MIC was done by broth microdilution method conferring to the 
reference of Clinical and Laboratory Standards Institute 2012, USA, 
using 96 well ELIZA plates [45]. To determine MIC, the compounds 
and the standard drug Ketoconazole (reference antimycotic drug) 
were dissolved in DMSO to give a stock concentration of 1 mg/ml. 
From these serial dilutions of the test, compounds were prepared in 
appropriate concentrations ranging from 0.5 to 1000µg/ml. Each 
well was inoculated with 50 µl of fungal suspension to give a final 
concentration of 1 x 105cfu/ml. The microtitre plates were incubated 
at 37 °C for 48 h. The fungal growth was measured by taking 
absorbance at 600 nm using a microtitre plate reader. 0.5% DMSO 
and sterile RPMI medium were used as blank control, which does 
not inhibit the growth of fungus. MIC was defined as the lowest 
concentration of drug showing no growth. The experiment was 
performed in triplicate.  
Minimum fungicidal concentration (MFC) 
MFC was determined as the lowest concentration of compound that 
that kills 99.9% of the fungal cells after 24 h incubation at 37 °C. MFC 
values were determined by removing 100 µl of fungal suspension 
from culture demonstrating no visible growth in MIC experiment 
and inoculating in fresh nutrient agar plates. Plates were incubated 
at 37 °C for a total period of 24 h. The MFC is determined with the 
wells whose concentrations are greater than MIC. Each experiment 
was repeated at least 3 times 
Antibacterial assay 
Test bacterial pathogens 
The bacterial pathogens used in the study were gram-positive 
bacteria Bacillus cereus, Staphylococcus aureus, gram-negative 
bacteria, Escherichia coli, Pseudomonas aeruginosa and Klebsiella 
pneumoniae. All the strains used were MTCC and procured from 
Microbial Type Culture Collection and Gene Bank, CSIR-IMTECH, 
Chandigarh, India. 
Sub-culturing of test organism 
All bacterial reference cultures were subcultured on nutrient agar. 
The bacterial slants were incubated overnight at 37 °C. Mcfarland 
density (0.5 on the McFarland scale) of bacterial culture was 
adjusted in normal saline to achieve the final concentration of 1 x 
105cfu/ml of each test organism individually. 
Determination of MIC 
MIC was done by broth microdilution method recommended by 
the National Committee for Clinical Laboratory Standards Institute 
2012 USA using 96 well ELIZA plates [46]. To determine the MIC, 
the compounds and standard drug ampicillin were dissolved in 
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0.5% DMSO to give a stock concentration of 1000 µg/ml. Colony 
suspensions equivalent to 0.5 McFarland standard were prepared 
and inoculated to yield an inoculum of 1 x 105cfu/ml. The 
microtitre plates were incubated at 37 °C for 24 h. The MIC was 
defined as the lowest concentration of drug showing no growth. 
MIC was attained from there independent tests that were 
performed in triplicate. 
Minimal bactericidal concentration (MBC) 
MBC was determined as the lowest concentration of compounds that 
kills 99.9% of the bacterial cells after 24h incubation at 37 °C. MBC 
values were determined by removing 100 µl of bacterial suspension 
from culture demonstrating no visible growth in MIC experiment 
and inoculating in fresh nutrient agar plates. Plates were incubated 
at 37 °C for a total period of 24 hr. The MBC is determined with the 
wells whose concentrations are greater than MIC. Each experiment 
was repeated at least 3 times. 
RESULTS AND DISCUSSION 
Chemistry 
The designed molecular framework i.e. 5-benzylidene 3-(dialkylamino) 
alkyl-2-thioxothiazolidin-4-one has been synthesised as per scheme 1.  
 
 
Scheme 1: Reagents and condition: a) Ammonium acetate, 
Acetic acid, 80-85 °C
 
Table 2: Synthesised derivatives 
Compound code  NR1R2  n  R 
 D1  dimethyl amino   2  Phenyl 
 D2  dimethyl amino   2  4-ethyl,-phenyl 
 D3  dimethyl amino   2  4-methyl phenyl 
 D4  diethyl amino   2  4-ethyl phenyl 
 D5   dimethyl amino   2  2-methyl phenyl 
 D6   dimethyl amino   2  4-isopropyl phenyl 
 D7   diethyl amino  2  Phenyl 
 D8  diethyl amino  2  4-methyl phenyl 
 D9  diethyl amino  2   2-methyl phenyl 
 D10  diethyl amino  2  4-isopropyl phenyl 
 
Spectral characterization of synthesised compounds 
5-Benzylidene-3-(2-(dimethylamino) ethyl)-2-thioxo-thiazolidin-
4-one (D1) 
Brown solid (Yield 66%), mp 105 °C; IR (KBr)  (cm-1): 2932, 2851, 
1701, 1236, 1175, 1120; 1H NMR (500 MHz, DMSO): 2.36 (6H, s), 
2.69-2.72 (2H, t), 4.23-4.26 (2H, t), 7.35-7.40 (4H, m), 7.63 (1H, s), 
7.80-7.84 (1H, m); 13C (125 MHz, DMSO): 193.55 (C=S), 167.87 
(C=O), 139.30, 133.36, 133.22, 130.74, 130.64, 129.61, 129.34, 
123.04, 114.07, 55.33, 45.34, 41.97, 29.70; HRMS (m/z) calculated 
for C14H16N2OS2: 292.0704, found: 293.0777 (MH+). 
3-(2-(dimethylamino) ethyl)-5-(4-ethylbenzylidene)-2-thioxo-
thiazolidin-4-one (D2) 
Dark brown solid (Yield 65%), mp 96 °C; IR (KBr)  (cm-1): 2928, 
2859, 1563, 1328, 1282, 1235, 1231; 1H NMR (500 MHz, DMSO): 
1.19 (3H, bs), 2.30 (6H, s), 2.61-2.67 (4H, m), 4.20-4.23 (2H, t), 
7.19-7.23 (2H, m), 7.27-7.33 (2H, m), 7.62 (1H, s); 13C (125 MHz, 
DMSO): 192.02 (C=S), 167.92 (C=O), 133.43, 130.87, 129.98, 
128.93, 128.55,121.80, 55.16, 45.12, 41.76, 28.92, 15.12; HRMS 
(m/z) calculated for C16H20N2OS2: 320.1017, found: 321.1086 (MH+). 
3-(2-(dimethylamino)ethyl)-5-(4-methylbenzylidene)-2-
thioxothiazolidin-4-one (D3) 
Yellow coloured solid (Yield 70%), mp 102 °C; IR (KBr)  (cm-1): 
2917, 2855, 2786, 1701, 1590, 1334, 1180; 1H NMR (500 MHz, 
DMSO), δ2.25 (6H, s), 2.33 (3H, s), 2.56-2.59 (2H, t), 4.17-4.20 (2H, 
t), 7.20-7.21 (2H, d), 7.31-7.32 (2H, d), 7.63 (1H, s); 13C (125MHz, 
DMSO):δ 193.57 (C=S), 167.91 (C=O), 141.63, 133.35, 130.74, 
130.67, 130.13, 121.81, 55.53, 45.61, 42.27, 21.64; HRMS (m/z) 
calculated for C15H18N2OS2: 306.0861 found: 307. 0.0930 (MH+). 
3-(2-(diethylamino)ethyl)-5-(4-ethyl benzylidene)-2-thioxo-
thiazolidin-4-one (D4) 
Yellow coloured solid (Yield 68%), mp 108 °C; IR (KBr)  (cm-1): 
2928, 2855, 1699, 1594, 1283; 1H NMR (500 mHz, DMSO), δ0.98-
1.01 (6H, t), 1.18-1.19 (3H, t), 2.55-2.74 (10H=2H x 5, m), 7.23-7.24 
(2H, d), 7.34-7.35 (2H, d), 7.63 (1H, s); 13C (125 MHz, DMSO); δ 
192.04 (C=S), 167.87 (C=O), 147.84, 133.27, 130.89, 128.94, 121.87, 
48.36, 47.37, 42.01, 28.92, 15.26, 15.14, 14.12, 11.91; HRMS (m/z) 
calculated for C18H24N2OS2: 348.1330, found: 349.1415 (MH+). 
3-(2-(dimethylamino)ethyl)-5-(2-methylbenzylidene-2-
thioxothiazolidin-4-one (D5) 
Dark brown coloured solid (Yield 68%); mp 115 °C; IR (KBr)  (cm-
1): 2627, 1725, 1431, 1356, 1310, 1291; 1H NMR (500 MHz, DMSO): 
δ2.27 (6H, s), 2.39 (3H, s), 2.58-2.61 (4H, m), 7.19-7.33 (4H, m), 7.88 
(1H, s), 13C (125MHz, DMSO): δ194.10 (C=S), 167.61 (C=O), 139.47, 
132.43, 131.17, 131.04, 130.71, 128.07, 126.70, 124.23, 55.50, 45.55, 
42.18, 29.70, 19.99; HRMS (m/z) calculated for C15H18N2OS2: 
306.0861, found: 307.0938 (MH+). 
3-(2-(dimethylamino)ethyl)-5-(4-isopropylbenzylidene)-2-
thioxothiazolidin-4-one (D6) 
Light brown coloured solid (Yield 70%); mp 110 °C; IR (KBr)  (cm-
1): 2966, 2924, 2790, 1703, 1592, 1326;1H NMR (500 MHz, DMSO); δ 
1.21-1.22 (6H, d), 2.26 (6H, s), 2.58-2.61 (2H, t) 2.87-2.92 (2H, m), 
4.84-4.94 (1H, m), 7.26-7.27 (2H, d), 7.35-7.36 (2H, d), 7.64 (1H, s); 
13C (125 MHz, DMSO): δ 192.04 (C=S), 167.95 (C=O), 152.41, 133.39, 
131.01, 130.93, 130.02, 127.54, 127.15, 114.08, 55.47, 45.53, 42.19, 
34.48, 34.22, 23.64; HRMS (m/z) calculated for C17H22N2OS2: 
334.1174, found: 335.1249 (MH+) 
5-benzyliden-3-(2-diethylamino)ethyl)-2-thioxothiazolidin-4-
one (D7) 
Dark brown coloured solid (Yield 68%); mp 125 °C; IR (KBr)  (cm-
1): 2928, 2855, 1699, 1592, 1283, 1176; 1H NMR (500 MHz, DMSO), 
δ1.01-1.04 (6H, t), 2.62-2.66 (4H, m), 2.77-2.80 (4H, m) 7.19-7.24 
(1H, m), 7.40-7.41 (4H, m), 7.65 (1H, s); 13C (125 mHz, DMSO); δ 
193.45 (C=S), 167.76 (C=O), 139.29, 133.13, 129.34, 127.91, 123.06, 
48.02, 47.16, 41.62, 11.52; HRMS (m/z) calculated for C14H20N2OS2: 
320.1017, found: 321.1083 (MH+). 
3-(2-(diethylamino)ethyl)-5-(4-methylbenzylidene)-2-thioxo-
thiazolidin-4-one (D8) 
Yellow coloured solid (Yield 68%); mp 112 °C; IR (KBr)  (cm-1): 
2928, 2855, 1699, 1592, 1282; 1H NMR (500MHz, DMSO); δ0.96-0.99 
(6H, t), 2.33-2.71 (11H= 3H+2H+2H+4H, m), 7.19-7.22 (2H, t), 7.31-
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7.33 (2H, d); 7.62 (1H, s); 13C (125MHz, DMSO): δ 193.54 (C=S), 
167.88 (C=O), 141.61, 133.20, 130.76, 130.13, 114.08, 48.55, 47.47, 
42.24, 21.64, 12.11; HRMS (m/z) calculated for C17H22N2OS2: 
334.1174, found: 335.1259 (MH+). 
3-(2-(diethylaminoethyl)-5-(2-methylbenzylidene)-2-
thioxothiazolidin-4-one (D9) 
Yellow coloured solid (Yield 70%); mp 112 °C; IR (KBr)  (cm-1): 
2928, 2851, 1699, 1594, 1283; 1H NMR (500MHz, DMSO); δ 0.97-
1.00 (6H, t), 2.39 (3H, s), 2.52-2.71 (8H= 4H+4H, m), 7.19-7.25 (3H, 
m), 7.25-7.34 (1H, m), 7.84 (1H, s); 13C (125MHz, DMSO): δ 194.05 
(C=S), 167.57 (C=O), 139.46, 132.44, 128.07, 126.71, 114.08, 48.56, 
47.53, 42.26, 20.00, 12.15; HRMS (m/z) calculated for C17H22N2OS2: 
334.1174, found: 335.1249 (MH+). 
3-(2-(diethylamino)ethyl)-5-(4-isopropylbenzylidene)-2-
thioxothiazolidin-4-one (D10) 
Light brown coloured solid (Yield 65%); mp 118 °C; IR (KBr)  (cm-1): 
2932, 2920, 2851, 1699, 1593, 1283, 1175; 1H NMR (500 MHz, DMSO), 
δ 0.98 (6H, s), 1.18-1.21 (6H, t), 2.54-2.88 (8H= 4H+2H+2H, m), 4.83-
4.94 (1H, m), 7.26-7.37 (4H, m), 7.63 (1H, s);13C (125MHz, DMSO): δ 
193.57 (C=S), 167.89 (C=O), 152.39, 141.14, 133.20, 130.93, 127.54, 
121.91, 48.51, 47.45, 42.21, 34.22, 23.64, 12.08; HRMS (m/z) 
calculated for C19H26N2OS2: 362.1487, found: 363.1571 (MH+). 
Antifungal activity 
All the compounds were screened for their in vitro antifungal activity 
against various species of Candida and Aspergillus niger. 
Ketoconazole was taken as the reference standard. Compounds with 
MIC>250µg/ml were considered as inactive. MIC between 250-125 
µg/ml was indicative of low activity and MIC between 64 to 32µg/ml 
exhibited moderate activity. MIC less than 16µg/ml can be 
considered as the activities which are used in the clinical situation. 
The MIC values of the compounds (D1-D10) against fungal 
pathogens are given in table 3. D10 was observed to show MIC value 
at 16µg/ml against Candida glabrata. Similarly, D6 also showed MIC 
value at 16µg/ml against Candida tropicalis and are considered as 
lead compounds for further development. The MFC values of the 
compounds against fungal pathogens are given in table 4. Compound 
D10 was observed to show MFC value at 32µg/ml against Candida 
glabrata and compound D6 showed MFC value at 32µg/ml against 
Candida tropicalis The structure-activity relationship studies 
revealed that the most potent compounds D6 (3-(2-
(dimethylamino)ethyl)-5-(4-isopropylbenzylidene)-2-
thioxothiazolidin-4-one)and D10(3-(2-(diethylamino) ethyl)-5-(4-
isopropyl benzylidene)-2-thioxothiazolidin-4-one) which are having 
4–isopropyl benzylidene group at 5thposition of rhodanine showed 
MIC value 16 µg/ml against candida albicans and Candida glabrata 
respectively.
 
Table 3: Minimum Inhibitory concentration of derivatives of D1-D10 against fungal pathogens 
Minimum Inhibitory concentration (µg/ml)* 
Fungal pathogens D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 ketoconazole 
Aspergillusniger 32 125 125 32 32 64 32 125 64 125 1 
Candida albicans 32 32 125 32 32 32 32 64 32 32 0.5 
Candida glabrata 64 64 125 64 32 64 32 64 64 16 0.5 
Candida parapsilosis 32 64 125 64 32 34 32 125 64 64 0.5 
Candida tropicalis 64 64 125 32 32 16 32 32 32 64 1 
*Values are average of three readings 
 
Table 4: Minimum fungicidal concentration of derivatives of D1-D10 against fungal pathogens 
Minimum fungicidal concentration (µg/ml)* 
Fungal pathogens D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 
Aspergillus niger 64 250 250 64 64 125 64 250 125 250 
Candida albicans 64 64 250 64 64 64 64 125 64 64 
Candida glabrata 125 125 250 125 64 125 64 125 125 32 
Candida parapsilosis 64 125 250 125 64 125 64 250 125 125 
Candida tropicalis 125 125 250 64 64 32 64 64 64 125 
*Values are average of three readings 
 
Antibacterial activity 
The MIC values of the compounds (D1-D10) and the positive control 
Ampicillin against the gram-positive bacterial strains (Bacillus cereus 
and Staphylococcus aureus) and gram-negative strains (Escherichia 
coli, Klebsiella pneumoniae, and Pseudomonas. aeruginosa) are given. 
The synthesized compounds (D1-D10, table 5) were also been 
evaluated for their antibacterial activities against different species. 
Ampicillin was taken as the reference standard. Compounds with 
MIC>250µg/ml were considered as inactive and MIC between 
250and 125µg/ml were indicative of low activity. MIC between 64 to 
32µg/ml showed moderate activity. MIC less than 16µg/ml was 
supposed to be the activity which can be used in the clinical 
situation. In table 4, D2 elicited a moderate antibacterial activity at 
MIC value of 32µg/ml in gram-negative strains, i. e, against 
Escherichia coli and Klebsiella pneumoniae. Compound D5 showed 
activity against Klebsiella pneumoniae at MIC value of 32µg/ml. But 
other compounds were observed to be rather resistant towards 
gram-positive strains. In comparison with Ampicillin which gave a 
MIC value of 1µg/ml in Escherichia coli, Klebsiella pneumonia, the 
results obtained with D2 and D5 were not very significant. The MBC 
values of the compounds (D1-D10) against both gram-positive and 
gram-negative strains are given in table 6. The MBC values of all the 
compounds were ≥ 64 µg/ml against all bacterial strains. 
 
Table 5: Minimum inhibitory concentration (µg/ml) of derivatives of D1-D10 against bacterial strains 
Minimum inhibitory concentration (µg/ml)* 
Pathogens D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 Ampicillin 
Bacillus cereus 64 125 250 125 64 125 64 125 125 125 2 
Staphylococcus aureus 64 62.5 250 125 64 125 64 125 125 125 0.5 
Escherichia coli  64 32 125 125 64 64 64 125 125 125 1 
Klebsiella pneumoniae 64 32 250 125 32 64 64 125 125 125 1 
Pseudomonas aeruginosa 64 250 250 250 250 250 250 250 250 250 1 
*Values are average of three readings 
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Table 6: Minimum bactericidal concentration (µg/ml) of derivatives of D1-D10 against bacterial strains 
Minimum bactericidal concentration (µg/ml)* 
Pathogens D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 
Bacillus cereus 125 250 500 250 125 250 125 250 250 250 
Staphylococcus aureus 125 125 500 250 125 250 125 250 250 250 
Escherichia coli 125 64 250 250 125 125 125 250 250 250 
Klebsiella pneumoniae 125 64 500 250 64 125 125 250 250 250 
Pseudomonas aeruginosa 125 500 500 500 500 500 500 500 500 500 
*Values are average of three readings 
 
Structural modifications of rhodanine derivatives results in 
compounds with a broad spectrum of pharmacological activities 
[47]. Substitution of various benzylidene derivatives at 5th position 
increases hydrophobicity and led to an increase in antimicrobial 
activity [48]. It has been reported that, the presence of the 
hydrophobic phenylalanine side chain at the N3-position and the 
electron-deficient benzylidene moiety at the C5-position of the 
rhodanine scaffold is responsible for the antibacterial activity of 
these compounds against methicillin-resistant Staphylococcus 
aureus [49]. In our study 4-ethylbenzylidene and 2-
methylbenzylidene group at 5thposition of rhodanine showed good 
antibacterial activity at 32μg/ml. A series of benzylidene–
rhodanines were reported to be acting as antifungal agents which 
are most active against Candida genus and Candida neoformans [50]. 
In our study, 4–isopropyl benzylidene group at 5thposition of 
rhodanine showed MIC value 16 µg/ml against candida albicans and 
Candida glabrata, respectively. 
CONCLUSION  
In the search for a novel antimicrobial agent different 5-benzylidene 
substituted rhodanine derivatives were synthesized from various N-
substituted rhodanine derivatives. All the ten synthesized compounds 
were screened for antimicrobial activity using the microdilution 
method recommended by the National Committee for Clinical 
Laboratory Standards, USA (CLSI 2006) to assess their antimicrobial 
activity. All the compounds exhibited good antifungal activity and 
compound D6(3-(2-(dimethylamino)ethyl)-5-(4-isopropyl 
benzylidene)-2-thioxothiazolidin-4-one) and D10(3-(2-(diethylamino) 
ethyl)-5-(4-isopropyl benzylidene)-2 thioxothiazolidin-4-one) which 
are having 4–isopropyl benzylidene group at 5thposition of rhodanine 
showed MIC value 16 µg/ml against candida tropicalis and Candida 
glabrata respectively. Compounds D2 and D5 Showed good 
antibacterial activity at 32 µg/ml. All the other compounds showed 
moderate antibacterial activity. Based on these results, it can be 
suggested these compounds may lead to the development of more 
potent antimicrobial agents in the future. 
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